NDA 022408 · Cipher
Natroba
Spinosad · Topical · Pediculicide
NovelLast checked: Nov 20, 2026Latest source record: Apr 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jan 18, 2011
Approved uses
3
Original approval plus efficacy supplements
Registered trials
13
4 Phase 3, 0 recruiting
FAERS reports
47
13 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 4, 2026.
Spinosad Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. ( 1.1 ) Spinosad Topical Suspension is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older. ( 1.2 ) 1.1 Head Lice Infestations Spinosad Topical Suspension is indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. Adjunctive Measures for Head Lice Infestations Spinosad Topical Suspension should be used in the context of an overall lice management program: Wash in hot water or dry-clean all recently worn clothing, hats, used bedding and towels. Wash personal care items such as combs, brushes and hair clips in hot water. A fine-tooth comb or special nit comb may be used to remove dead lice and nits. 1.2 Scabies Infestations Spinosad Topical Suspension is indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older. Adjunctive Measures for Scabies Infestations Wash in hot water or dry-clean any bedding, clothing and towels used by anyone having scabies.
Mechanism: Spinosad causes neuronal excitation in insects. After periods of hyperexcitation, lice and mites become paralyzed and die.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 28, 2021 Supplement 10 · Efficacy LetterLabel
- Dec 30, 2014 Supplement 5 · Efficacy LabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Jan 18, 2011 Original approval · Type 1 - New Molecular Entity NovelReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- NATROBA · SPINOSAD 0.9% · SUSPENSION, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Spinosad" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head LicePivotal-lookingCompleted
ParaPRO LLCIndustry
NCT00545753 · 558 participants · Start Sep 2007 · Primary completion Mar 2008
Drug: Spinosad; Spinosad and 1 more · For: Pediculosis
Sites: Scottsdale, Arizona; Hot Springs, Arkansas; Beverly Hills, California · 6 sites in all
- Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head LicePivotal-lookingCompleted
ParaPRO LLCIndustry
NCT00545168 · 480 participants · Start Sep 2007 · Primary completion Mar 2008
Drug: Spinosad; Spinosad and 1 more · For: Pediculus Capitis Infestation
Sites: Ormond Beach, Florida; West Palm Beach, Florida; Indianapolis, Indiana · 6 sites in all
- Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of ScabiesPivotal-lookingCompleted
ParaPRO LLCIndustry
NCT02485717 · 291 participants · Start May 2, 2017 · Primary completion Jun 25, 2018
Drug: spinosad topical suspension, 0.9% · For: Scabies
Sites: Elk Grove, California; Kissimmee, Florida; Miami, Florida · 5 sites in all
- Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of ScabiesPivotal-lookingCompleted
ParaPRO LLCIndustry
NCT02485704 · 280 participants · Start May 10, 2017 · Primary completion Aug 3, 2018
Drug: spinosad topical suspension, 0.9% · For: Scabies
Sites: Anaheim, California; Long Beach, California; Kissimmee, Florida · 7 sites in all
- Comparison of Topical Permethrin 5% and Spinosad 0.9% for Scabies TreatmentPivotal-lookingNot yet recruiting
University of FaisalabadAcademic, hospital or other
NCT07935343 · 180 participants (planned) · Start Feb 2027 · Primary completion Jul 2027
Drug: Permethrin 5%; spinosad topical suspension, 0.9% · For: Scabies
Sites: Faisalābad, Pakistan
- A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis CapitisPivotal-lookingCompleted
ParaPRO LLCIndustry
NCT00311779 · 120 participants · Start Mar 2006
Drug: Spinosad Creme Rinse · For: Pediculosis Capitis (Head Lice)
Sites: Scottsdale, Arizona; West Palm Beach, Florida; Miamiville, Ohio
Aperta Biosciences, LLCIndustry
NCT06720896 · 66 participants · Start Nov 1, 2025 · Primary completion Jul 13, 2026
Drug: APT-001 topical ophthalmic ointment (spinosad); Vehicle control for APT-001 topical ophthalmic ointment · For: Blepharitis
Sites: Guatemala City, Guatemala · 2 sites in all
ParaPRO LLCIndustry
NCT00605956 · 65 participants (planned) · Start Jan 2008 · Primary completion Feb 2008
Drug: NatrOVA Creme Rinse - 1%; NatrOVA Creme Rinse Vehicle Only and 1 more · For: Head Lice
Sites: St. Petersburg, Florida
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective15
- pruritus7
- alopecia5
- rash4
- condition aggravated3
- erythema3
- abdominal pain upper2
- burning sensation2
- death2
- headache2
- lice infestation2
- paraesthesia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Natroba (Spinosad)
2024 spending
$161K
Beneficiaries
440
580 claims
Per beneficiary
$367
$2.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $82,555 |
| 2021 | $51,021 |
| 2022 | $98,871 |
| 2023 | $131,063 |
| 2024 | $161,297 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Head lice.
Burgess IF · BMJ Clin Evid 2011 · Systematic Review
- Insect bite reactions.
Singh S, Mann BK · Indian J Dermatol Venereol Leprol 2013 · Systematic Review
- Laboratory and field efficacy of entomopathogenic fungi for the management of the sweetpotato weevil, Cylas formicarius (Coleoptera: Brentidae).
Reddy GV, Zhao Z, Humber RA · J Invertebr Pathol 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Spinosad at 0.9% in the treatment of scabies: Efficacy results from 2 multicenter, randomized, double-blind, vehicle-controlled studies.
Seiler JC, Keech RC, Aker JL, et al. · J Am Acad Dermatol 2022 · Multicenter Study, Randomized Controlled Trial
- Clinical field study of the safety and efficacy of spinosad chewable tablets for controlling fleas on dogs.
Robertson-Plouch C, Baker KA, Hozak RR, et al. · Vet Ther 2008 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Initial evaluations of the effectiveness of spinetoram as a long-acting, oral systemic pulicide for controlling cat flea (Ctenocephalides felis) infestations on dogs.
White WH, Riggs KL, Totten ML, et al. · Vet Parasitol 2017 · Randomized Controlled Trial
Sponsor: Cipher
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.